Oxford BioMedica/Sanofi Make Headway With FDA On TroVax Cancer Vaccine
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
After facing a setback with the therapeutic cancer vaccine TroVax in July, partners Oxford BioMedica and Sanofi-Aventis are reaffirming their commitment to develop the vaccine for the treatment of renal cancer and potentially colorectal cancer following a meeting with FDA
You may also be interested in...
Oxford BioMedica Stops New Dosing In TroVax Phase III
Fate of Sanofi-partnered drug in renal cancer could influence its path in colorectal, too.
Sanofi/Oxford BioMedica To Present Positive Phase II Data For Cancer Vaccine TroVax At ASCO
Oxford BioMedica anticipates filing a BLA in 2009 for RCC.
Sanofi Gains Therapeutic Cancer Vaccine TroVax In Deal With Oxford BioMedica
Announcement of the $690 million deal comes one day ahead of an advisory committee meeting for Provenge, the first therapeutic cancer vaccine to reach FDA.